Fam A G
Division of Rheumatology, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada.
Drugs Aging. 1998 Sep;13(3):229-43. doi: 10.2165/00002512-199813030-00006.
Gout in the elderly differs from classical gout found in middle-aged men in several respects: it has a more equal gender distribution, frequent polyarticular presentation with involvement of the joints of the upper extremities, fewer acute gouty episodes, a more indolent chronic clinical course, and an increased incidence of tophi. Long term diuretic use in patients with hypertension or congestive cardiac failure, renal insufficiency, prophylactic low dose aspirin (acetylsalicylic acid), and alcohol (ethanol) abuse (particularly by men) are factors associated with the development of hyperuricaemia and gout in the elderly. Extreme caution is necessary when prescribing nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of acute gouty arthritis in the elderly. NSAIDs with short plasma half-life (such as diclofenac and ketoprofen) are preferred, but these drugs are not recommended in patients with peptic ulcer disease, renal failure, uncontrolled hypertension or cardiac failure. Colchicine is poorly tolerated in the elderly and is best avoided. Intra-articular and systemic corticosteroids are increasingly being used for treating acute gouty flares in aged patients with medical disorders contraindicating NSAID therapy. Urate-lowering drugs are indicated for the treatment of hyperuricaemia and chronic gouty arthritis. Uricosuric drugs are poorly tolerated and the frequent presence of renal impairment in the elderly renders these drugs ineffective. Allopurinol is the urate-lowering drug of choice, but its use in the aged is associated with an increased incidence of both cutaneous and severe hypersensitivity reactions. To minimise this risk, allopurinol dose must be kept low. A starting dose of allopurinal 50 to 100mg on alternate days, to a maximum daily dose of about 100 to 300mg, based upon the patient's creatinine clearance and serum urate level, is recommended. Asymptomatic hyperuricaemia is not an indication for long term urate-lowering therapy; the risks of drug toxicity often outweigh any benefit.
其性别分布更为均衡,常表现为多关节受累,包括上肢关节,急性痛风发作次数较少,慢性临床病程更为隐匿,且痛风石发生率增加。高血压或充血性心力衰竭患者长期使用利尿剂、肾功能不全、预防性低剂量阿司匹林(乙酰水杨酸)以及酒精(乙醇)滥用(尤其是男性)是与老年人高尿酸血症和痛风发生相关的因素。为老年人急性痛风性关节炎开非甾体抗炎药(NSAIDs)进行治疗时必须格外谨慎。首选血浆半衰期短的NSAIDs(如双氯芬酸和酮洛芬),但不建议给患有消化性溃疡病、肾衰竭、未控制的高血压或心力衰竭的患者使用这些药物。秋水仙碱在老年人中耐受性差,最好避免使用。对于有NSAID治疗禁忌的老年疾病患者,关节内和全身性皮质类固醇越来越多地用于治疗急性痛风发作。降尿酸药物用于治疗高尿酸血症和慢性痛风性关节炎。促尿酸排泄药物耐受性差,且老年人常存在肾功能损害,使得这些药物无效。别嘌醇是降尿酸的首选药物,但在老年人中使用会增加皮肤和严重过敏反应的发生率。为将此风险降至最低,别嘌醇剂量必须保持低水平。建议根据患者的肌酐清除率和血清尿酸水平,开始剂量为别嘌醇50至100mg隔日一次,最大每日剂量约为100至300mg。无症状高尿酸血症并非长期降尿酸治疗的指征;药物毒性风险往往超过任何益处。